EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Open Access · CC BY-NC-ND 4.0

Efficacy of long‐term risankizumab treatment for moderate‐to‐severe plaque psoriasis: Subgroup analyses by baseline characteristics and psoriatic disease manifestations through 256 weeks ( LIMMitless trial)

Bruce Strober iD, Hervé Bachelez iD, Jeffrey Crowley iD, Boni E Elewski iD, Melinda Gooderham iD, Alan Menter iD, Robert Strohal iD, Michael M Chen iD, Tianshuang Wu, Tianyu Zhan iD, Huzefa Photowala, April Armstrong iD

Journal of the European Academy of Dermatology and Venereology · 2024

DOI: 10.1111/jdv.19748 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of the European Academy of Dermatology and Venereology, 2024. Verfasst von Bruce Strober und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Yale University, New Haven, Connecticut, USA. Hauptthemen laut MEDLINE: Psoriasis, Severity of Illness Index. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Psoriasis is an inflammatory skin disease that impacts a heterogeneous group of patients and can have multiple clinical manifestations. Risankizumab is approved for the treatment of moderate‐to‐severe plaque psoriasis.

Objectives

To evaluate the long‐term efficacy of risankizumab according to baseline patient characteristics, and for the treatment of high‐impact disease manifestations (nail, scalp and palmoplantar psoriasis), through 256 weeks of continuous treatment in the phase 3 LIMMitless study.

Methods

This subgroup analysis evaluated pooled data from patients with moderate‐to‐severe plaque psoriasis who were randomized to risankizumab 150 mg during two double‐blind, phase 3, 52‐week base studies (UltIMMa‐1/2; NCT02684370/NCT02684357) and were enrolled in the phase 3 LIMMitless open‐label extension study (NCT03047395). Subgroup assessments included the proportion of patients who achieved ≥90%/100% improvement in Psoriasis Area and Severity Index (PASI 90/100). Among patients with nail, scalp and/or palmoplantar psoriasis in addition to skin psoriasis, assessments included changes from baseline in and resolution of these three psoriatic manifestations.

Results

Overall, a numerically similar proportion of patients ( N = 525) achieved PASI 90/100 through Week 256, regardless of their baseline age, sex, body mass index, weight, PASI or psoriatic arthritis status. Patients with nail, scalp and/or palmoplantar psoriasis experienced substantial improvements in manifestation‐specific indices (mean improvement from baseline to Week 256 of >81%, >94% and >97%, respectively); in patients with all three manifestations ( N = 121), 44.6% achieved complete clearance of these manifestations at Week 256.

Conclusions

Risankizumab demonstrated generally consistent efficacy through 256 weeks across patient subgroups and showed durable long‐term efficacy for psoriatic disease manifestations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PsoriasisSeverity of Illness IndexHumansMaleFemaleMiddle AgedDouble-Blind MethodAdultAntibodies, MonoclonalNail DiseasesTreatment OutcomeDermatologic Agents

Substanzen

risankizumabAntibodies, MonoclonalDermatologic Agents

Autor:innen und Institutionen

  • Department of Dermatology, Yale University, New Haven, Connecticut, USA.
  • Central Connecticut Dermatology Research, Cromwell, Connecticut, USA.
  • Department of Dermatology, Hôpital Saint-Louis AP-HP, Paris, France.
  • Department of Dermatology, Paris Cité University, Paris, France.
  • Bakersfield Dermatology and Skin Cancer Medical Group, Bakersfield, California, USA.
  • Department of Dermatology, University of Alabama at Birmingham School of Medicine, Birmingham, Alabama, USA.

ORCID-Profile: Bruce Strober, Hervé Bachelez, Jeffrey Crowley, Boni E Elewski, Melinda Gooderham, Alan Menter, Robert Strohal, Michael M Chen, Tianyu Zhan, April Armstrong

Zitieren

APA

Strober, B., Bachelez, H., Crowley, J., Elewski, B. E., Gooderham, M., Menter, A., Strohal, R., Chen, M. M., Wu, T., Zhan, T., Photowala, H., & Armstrong, A. (2024). Efficacy of long‐term risankizumab treatment for moderate‐to‐severe plaque psoriasis: Subgroup analyses by baseline characteristics and psoriatic disease manifestations through 256 weeks ( LIMMitless trial). Journal of the European Academy of Dermatology and Venereology. https://doi.org/10.1111/jdv.19748

Vancouver

Strober B, Bachelez H, Crowley J, Elewski BE, Gooderham M, Menter A, et al. Efficacy of long‐term risankizumab treatment for moderate‐to‐severe plaque psoriasis: Subgroup analyses by baseline characteristics and psoriatic disease manifestations through 256 weeks ( LIMMitless trial). Journal of the European Academy of Dermatology and Venereology. 2024. doi:10.1111/jdv.19748

BibTeX
@article{Strober2024,
  author = {Strober, Bruce and Bachelez, Hervé and Crowley, Jeffrey and Elewski, Boni E and Gooderham, Melinda and Menter, Alan and Strohal, Robert and Chen, Michael M and Wu, Tianshuang and Zhan, Tianyu and Photowala, Huzefa and Armstrong, April},
  title = {Efficacy of long‐term risankizumab treatment for moderate‐to‐severe plaque psoriasis: Subgroup analyses by baseline characteristics and psoriatic disease manifestations through 256 weeks ( LIMMitless trial)},
  journal = {Journal of the European Academy of Dermatology and Venereology},
  year = {2024},
  doi = {10.1111/jdv.19748}
}
Kostenlos starten →